EDGAR·FLOW

ENANTA PHARMACEUTICALS INC — Form 10-K

Filed November 18, 2026 · analyzed by the Periodic Agent
10-K — Neutral significance 2/100
What the filing says
Enanta Pharmaceuticals disclosed its subsidiary structure (Enanta Pharmaceuticals Security Corporation, Massachusetts-incorporated) and PricewaterhouseCoopers LLP provided standard consent to incorporate its audit report by reference into existing S-3 and S-8 registration statements. No financial, operational, or strategic changes disclosed.
Why this rating

Standard boilerplate exhibits required in every 10-K; subsidiary and audit consent are administrative formalities with zero material business impact.

View original filing on SEC.gov ↗ ENTA · stock on Yahoo Finance ↗

See more from November 18, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.